ArticleNature medicine2018
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 1 pooled it
13.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
213 citing papers in PubMed, 1 synthesis or guideline pooled it, 310 citations in OpenAlex.
- Disrupting Mechanisms that Regulate Genomic Repeat Elements to Combat Cancer and Drug Resistance.Frontiers in cell and developmental biology · 2022Pooled it
- Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.Nature cancer · 2021Trial
- The therapeutic potential of transposable element activity modulation.EMBO molecular medicine · 2026Review
- Viral mimicry escape as a necessary feature of malignant transformation.Nature reviews. Cancer · 2026Review
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Identification and validation of exosome-related biomarkers in pediatric glioblastoma.Discover oncology · 2026Article
- Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.Materials today. Bio · 2026Article
- Review
- In vivo CRISPR screens identify CBX4 as an epigenetic regulator for cancer immunotherapy.The Journal of clinical investigation · 2026Article
- Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.Cancer cell · 2026Article
- A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.Nature communications · 2026Article
- LSD1 ablation promotes mammary tumor metastasis by attenuating NK cell-mediated anti-tumor immunity.bioRxiv : the preprint server for biology · 2026Article
- Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis.Nature communications · 2026Article
- PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition.Communications biology · 2026Article
- CD38 degrades MAVS through mitophagy to inhibit type I interferon secretion in nasopharyngeal carcinoma cells and impairs CD8Nature communications · 2026Article
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.JCI insight · 2026Article
- Boosting Antiviral Defenses: stat3 Inhibition Enhances Type I Interferon Response to Respiratory Syncytial Virus by Silencing KAP1.Current molecular medicine · 2026Article
- Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report.Frontiers in oncology · 2026Article
- Activation of endogenous retroviruses in tumor cells and their immunomodulatory mechanisms: from molecular basis to clinical translation.Frontiers in oncology · 2026Review
153 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 13 institutions in 2 countries.
Israel CañadasDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rohit ThummalapalliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jong Wook KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shunsuke KitajimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Russell William JenkinsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6110-2148
Camilla Laulund ChristensenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marco CampisiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9288-5285
Yanan KuangBelfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Yanxi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Evisa GjiniDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Gao ZhangMelanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Tian TianDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Debattama Rai SenDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Diana MiaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1754-2319
Yu ImamuraGastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Tran ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brandon PielDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hideki TeraiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amir Reza ArefBelfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Timothy HaganDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shohei KoyamaDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan.
Masayuki WatanabeGastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Anika Elise AdeniDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Christine Anne LydonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pablo TamayoMoores Cancer Center and School of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9360-4668
Zhi WeiDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.ORCID http://orcid.org/0000-0001-6059-4267
Meenhard HerlynMelanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Thanh Uyen BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ravindra UppaluriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lynnette Marie ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Ewa SicinskaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacob SandsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Scott RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Kwok Kin WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cloud Peter PaweletzBelfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Hideo WatanabeDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David Allen BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. dbarbie@partners.org.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USHarvard University · USBroad Institute · USNew Jersey Institute of Technology · USThe Cancer Institute Hospital · JPThe Wistar Institute · USIcahn School of Medicine at Mount Sinai · USKumamoto University · JPMassachusetts General Hospital · USNYU Langone Health · USThe University of Osaka · JPUniversity of California San Diego · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MTuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9MTUMOR DEVELOPMENT AND PROGRESSION IN HUMAN MELANOCYTESP01CA025874 · NCI · WISTAR INSTITUTE · PI MARMORSTEIN, RONEN · 1985 to 2015
$19.0MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MA Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTargeting the cytokine circuitry of KRAS-driven lung cancerR01CA190394 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2015 to 2026
$4.5MMETASTATIS: BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPYR01CA047159 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1989 to 2015
$3.9MDevelopment of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint BlockadeU01CA214381 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BARBIE, DAVID A, KAMM, ROGER D · 2017 to 2021
$3.5MTargeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung CancerU01CA213333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GRAY, NATHANAEL SCHIANDER, WONG, KWOK KIN · 2017 to 2021
$3.3MGenePattern Notebooks for Cancer ResearchU24CA194107 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2015 to 2019
$2.8MNCI NIH HHS K99 CA201618NCI NIH HHS P01 CA025874NCI NIH HHS P01 CA114046NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA047159NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA190394NCI NIH HHS U01 CA213333NCI NIH HHS U01 CA214381NCI NIH HHS U01 CA217885NCI NIH HHS U24 CA194107
Abstract
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance
Indexed as
AnimalsCell Line, TumorEndogenous RetrovirusesGene Expression Regulation, NeoplasticHumansImmunity, InnateInterferonsMice, NudeNeoplasmsRNA, AntisenseInterferonsRNA, Antisense
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.